<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1054151198438221&amp;ev=PageView&amp;noscript=1">

The Article Galaxy Blog

Webinar: Take a Deep Dive Into 'Fail Fast' Methodology

Lettie Y. Conrad|Product & Publishing Consultant
Lettie Y. Conrad|Product & Publishing Consultant
June 11, 2020

At this moment in history, scientists, researchers, and innovative companies across the globe are working around the clock to develop a safe and effective treatment or vaccine for COVID-19. But as you likely know, it typically takes 10 to 15 years to develop a new drug therapy, conduct clinical trials, and pass regulatory requirements. What’s more, only 9.6% of the drugs that enter clinical trials are approved by the Food and Drug Administration. In short, drug developers are facing an uphill battle as they seek to accelerate product development and improve clinical outcomes.

If you've been following our blog for a while, you may have read our post on “Fail Fast” methodology, which focuses on spotting potential dead-ends early in the drug development cycle in order to reduce R&D costs, improve clinical outcomes, and speed time to market.

The fail fast methodology is particularly important for small and medium-sized enterprises (SMEs) in the biopharmaceutical market. Often, these companies do not have the resources to compete with big pharma and develop a successful drug on their own. Therefore, 'failing faster' and recognizing potential pitfalls early on - ahead of costly clinical trials - becomes ever more critical.

Want to take a deeper dive into this timely topic?

Join us for a complimentary webinar! Hosted by FierceBiotech, you'll hear from a panel of experts in biopharma discovery, R&D, and clinical trial design as they discuss the benefits and challenges of a fail fast strategy. Representatives from companies that have successfully adopted this innovative approach will participate as well, offering valuable insights on what worked—and what did not.

You'll learn:

  • When to implement 'fail fast' for maximum cost savings
  • How to use 'fail fast' tactics to validate drug targets
  • Where to shift your R&D strategies for optimal success


Reserve your spot now:
Fail Faster: How Biopharma Companies Can Capitalize on Early Drug Development Failures

Date: Friday, June 19th, 2020
Time: 11am ET / 8am PT
Duration: 1 hour

register-for-the-webinar

Read

At this moment in history, scientists, researchers, and innovative companies across the globe are working around the clock to develop a safe and effective treatment or vaccine for COVID-19. But as you likely know, it typically takes 10 to 15 years to develop a new drug therapy, conduct clinical trials, and pass regulatory requirements. What’s more, only 9.6% of the drugs that enter clinical trials are approved by the Food and Drug Administration. In short, drug developers are facing an uphill battle as they seek to accelerate product development and improve clinical outcomes.

If you've been following our blog for a while, you may have read our post on “Fail Fast” methodology, which focuses on spotting potential dead-ends early in the drug development cycle in order to reduce R&D costs, improve clinical outcomes, and speed time to market.

The fail fast methodology is particularly important for small and medium-sized enterprises (SMEs) in the biopharmaceutical market. Often, these companies do not have the resources to compete with big pharma and develop a successful drug on their own. Therefore, 'failing faster' and recognizing potential pitfalls early on - ahead of costly clinical trials - becomes ever more critical.

Want to take a deeper dive into this timely topic?

Join us for a complimentary webinar! Hosted by FierceBiotech, you'll hear from a panel of experts in biopharma discovery, R&D, and clinical trial design as they discuss the benefits and challenges of a fail fast strategy. Representatives from companies that have successfully adopted this innovative approach will participate as well, offering valuable insights on what worked—and what did not.

You'll learn:

  • When to implement 'fail fast' for maximum cost savings
  • How to use 'fail fast' tactics to validate drug targets
  • Where to shift your R&D strategies for optimal success


Reserve your spot now:
Fail Faster: How Biopharma Companies Can Capitalize on Early Drug Development Failures

Date: Friday, June 19th, 2020
Time: 11am ET / 8am PT
Duration: 1 hour

register-for-the-webinar

The Author

    Lettie Y. Conrad|Product & Publishing Consultant

Lettie brings nearly 20 years’ experience in scholarly publishing to her diverse portfolio of product research and development projects. She is dedicated to helping information organizations cultivate a user-centered, standards-compliant approach to digital publishing and academic programs. Her expertise lies in optimizing user engagement for content discovery and access of academic content platforms. Previously, Lettie played a key role in establishing the product management program at SAGE Publishing. Currently, Lettie is North American Editor for Learned Publishing, a ‘chef’ with the SSP’s Scholarly Kitchen blog, and Information Science PhD candidate at the Queensland University of Technology, Brisbane.

Topics

research, R&D, biopharma, scientists, drug development, vaccine, webinar, fail fast, methodology

Ready to See
Article Galaxy in Action?

Schedule a call with one of our advisors. We will get you started with a FREE 14-day trial, with no obligation.

REQUEST MORE INFORMATION